Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session.

Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary o.

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

AstraZeneca

Pfizer

There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfolio that's overweight growth stocks.

3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains

We believe that the computing behemoth IBM (NYSE: IBM) is currently a better pick over the pharmaceuticals giant Merck (NYSE: MRK). The decision to invest often comes down to finding the best stocks within the scope of certain characteristics that suit an investment style.

With Robust AI Prospects Is IBM A Better Pick Over Merck Stock Within The Dow Index?

Intellia Therapeutics

Arrowhead Pharmaceuticals

Verona Pharma

X4 Pharmaceuticals Inc

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out.

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Pfizer currently dominates the market for pneumococcal vaccines. Merck aims to change that.

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's  (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease.

Merck Stock Edges Higher on FDA Vaccine Approval

Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.

Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

Merck said on Monday the U.S. Food and Drug Administration has approved its next-generation vaccine to protect adults against pneumococcal disease.

US FDA approves Merck's pneumococcal vaccine for adults

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease & Pneumococcal Pneumonia in Adults.

U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemotherapy as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia. An advisory panel to the Centers for Disease Control and Prevention will meet on June 27 to discuss who should be eligible for the shot, called Capvaxive

FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections

Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products.

Merck's vaccine approval poses threat to one of Pfizer's top-selling products

In the closing of the recent trading day, Merck (MRK) stood at $130.20, denoting a -1.24% change from the preceding trading day.

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference.

Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript)

Merck is focused on second and third-generation opportunities in the cardiometabolic drugs market, which includes treatments for obesity, the drugmaker said at a healthcare conference on Tuesday.

Merck looks for next-generation opportunities in obesity

Genuine Parts

Starbucks

High-yield  dividend stocks typically distribute a significant portion of their profits back to shareholders in the form ofdividends. In addition to regular dividend income, such shares offer the potential for capital appreciation.

3 High-Yield Dividend Stocks to Collect Impressive Payouts Year After Year

MercadoLibre

Palantir Technologies

High-cap stocks are usually the headline stealers and attract the most attention from investors looking for stocks to buy. However, there is some upside to investing in lesser-known stocks.

From $10k to $100k: 3 Stocks With the Potential for Amazing Returns

Merck's Keytruda drug has shown promising results in treating bowel cancer, according to Germany's largest newspaper. Merck has significantly increased its oncology portfolio, with Keytruda achieving nine U.S. approvals in earlier-stage cancers. The company's phase III trials targeting earlier-stage cancers have shown impressive outcomes, including a reduction in the risk of death for patients with lung and renal cell cancers.

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Several notable billionaire hedge fund managers have bought shares of Pfizer or Merck recently. Despite immediate or upcoming headwinds, both companies look like strong picks for income investors.

2 Dividend Stocks Billionaires Are Buying: Should You?

DARMSTADT, Germany--(BUSINESS WIRE)--Merck opened its expanded Life Science distribution center in Schnelldorf, Germany. The € 180 investment added 25,000 square meters to the site.

Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center

The latest trading day saw Merck (MRK) settling at $129.45, representing a +0.57% change from its previous close.

Merck (MRK) Ascends But Remains Behind Market: Some Facts to Note

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Merck & Co., Inc. (NYSE:MRK ) Investor Event at ASCO 2024 June 3, 2024 7:00 PM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Dean Li - President of Merck Research Labs Eliav Barr - Chief Medical Officer & Head of Global Clinical Development Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Joanne Monahan - Senior Vice President, US Oncology Conference Call Participants Carter Gould - Barclays Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Akash Tewari - Jefferies Steve Scala - TD Cowen Chris Shibutani - Goldman Sachs Trung Huynh - UBS Mohit Bansal - Wells Fargo Dan Ziment - Morgan Stanley Daina Graybosch - Leerink Partners Operator Thank you for standing by. Welcome to the Merck & Co., Inc. Investor Event at the American Society of Clinical Oncology Annual Meeting.

Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript)

Moderna

Cancer vaccines are finally showing promise as Moderna and Merck touted promising data on an experimental skin cancer vaccine and the U.K. announced plans for a “landmark” scheme to test the technology across the country this week, after decades of research that could bring a new era of personalized medicine.

News for Merck Stock (MRK)